APLS
Price
$22.49
Change
-$0.51 (-2.22%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.89B
28 days until earnings call
CRSP
Price
$32.65
Change
-$1.54 (-4.50%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
2.93B
39 days until earnings call
Ad is loading...

APLS vs CRSP

Header iconAPLS vs CRSP Comparison
Open Charts APLS vs CRSPBanner chart's image
Apellis Pharmaceuticals
Price$22.49
Change-$0.51 (-2.22%)
Volume$44.52K
Capitalization2.89B
CRISPR Therapeutics AG
Price$32.65
Change-$1.54 (-4.50%)
Volume$51.2K
Capitalization2.93B
APLS vs CRSP Comparison Chart
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. CRSP commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a StrongBuy and CRSP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (APLS: $23.00 vs. CRSP: $34.19)
Brand notoriety: APLS and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 148% vs. CRSP: 79%
Market capitalization -- APLS: $2.83B vs. CRSP: $2.93B
APLS [@Biotechnology] is valued at $2.83B. CRSP’s [@Biotechnology] market capitalization is $2.93B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, both APLS and CRSP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 4 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • APLS’s TA Score: 4 bullish, 4 bearish.
  • CRSP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, APLS is a better buy in the short-term than CRSP.

Price Growth

APLS (@Biotechnology) experienced а -3.32% price change this week, while CRSP (@Biotechnology) price change was -12.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

APLS is expected to report earnings on May 01, 2025.

CRSP is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($2.93B) and APLS($2.89B) have the same market capitalization . CRSP YTD gains are higher at: -13.135 vs. APLS (-27.922). APLS has higher annual earnings (EBITDA): -154.53M vs. CRSP (-447.31M). CRSP has more cash in the bank: 1.9B vs. APLS (411M). CRSP has less debt than APLS: CRSP (224M) vs APLS (470M). APLS has higher revenues than CRSP: APLS (781M) vs CRSP (35M).
APLSCRSPAPLS / CRSP
Capitalization2.89B2.93B98%
EBITDA-154.53M-447.31M35%
Gain YTD-27.922-13.135213%
P/E RatioN/AN/A-
Revenue781M35M2,231%
Total Cash411M1.9B22%
Total Debt470M224M210%
FUNDAMENTALS RATINGS
APLS vs CRSP: Fundamental Ratings
APLS
CRSP
OUTLOOK RATING
1..100
1458
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
8688
P/E GROWTH RATING
1..100
10076
SEASONALITY SCORE
1..100
n/a48

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (67) in the Biotechnology industry is in the same range as APLS (73) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as APLS (98) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

APLS's Price Growth Rating (86) in the Medical Distributors industry is in the same range as CRSP (88) in the Biotechnology industry. This means that APLS’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (76) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCRSP
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CEUCX52.740.15
+0.29%
American Funds Europacific Growth 529C
FSLCX17.53N/A
N/A
Fidelity Small Cap Stock
NMMGX10.25N/A
N/A
Northern Multi-Manager Glbl Real Estate
IFUTX26.15N/A
N/A
Invesco Dividend Income R6
RREYX29.14-0.20
-0.68%
Russell Inv Global Real Estate Secs Y

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NTLA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+1.41%
NTLA - APLS
41%
Loosely correlated
+9.69%
BEAM - APLS
40%
Loosely correlated
+4.79%
CRSP - APLS
40%
Loosely correlated
+3.17%
DNLI - APLS
39%
Loosely correlated
+11.80%
IGMS - APLS
39%
Loosely correlated
+6.96%
More